172 related articles for article (PubMed ID: 38687785)
1. Structural insights into human MHC-II association with invariant chain.
Wang N; Waghray D; Caveney NA; Jude KM; Garcia KC
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2403031121. PubMed ID: 38687785
[TBL] [Abstract][Full Text] [Related]
2. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
3. Stoichiometry of HLA class II-invariant chain oligomers.
Koch N; Zacharias M; König A; Temme S; Neumann J; Springer S
PLoS One; 2011 Feb; 6(2):e17257. PubMed ID: 21364959
[TBL] [Abstract][Full Text] [Related]
4. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
6. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
[TBL] [Abstract][Full Text] [Related]
7. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
8. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
10. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
11. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
12. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
13. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II.
Chou CL; Sadegh-Nasseri S
J Exp Med; 2000 Dec; 192(12):1697-706. PubMed ID: 11120767
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion.
Neumann J; Eis-Hübinger AM; Koch N
J Immunol; 2003 Sep; 171(6):3075-83. PubMed ID: 12960333
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain-MHC class II complexes: always odd and never invariant.
Cresswell P; Roche PA
Immunol Cell Biol; 2014 Jul; 92(6):471-2. PubMed ID: 24777311
[No Abstract] [Full Text] [Related]
16. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
17. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
[TBL] [Abstract][Full Text] [Related]
18. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
19. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.
Karosiene E; Rasmussen M; Blicher T; Lund O; Buus S; Nielsen M
Immunogenetics; 2013 Oct; 65(10):711-24. PubMed ID: 23900783
[TBL] [Abstract][Full Text] [Related]
20. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins.
Harris PE; Maffei A; Colovai AI; Kinne J; Tugulea S; Suciu-Foca N
Blood; 1996 Jun; 87(12):5104-12. PubMed ID: 8652823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
